India Innovation Fund (IIF)  along with Blume Ventures as co-investor, has made an investment in

Shantani’s proprietary chemical proteomics technology platform is used to identify and validate a few but rightful targets (cellular binding partners) of drugs and drug like bioactive molecules in a very short period of time allowing savings of 50-70 per cent in cost and time over existing strategies. It is also valuable for drug repositioning purposes and for identifying off-target interactions of a drug to understand its toxicity profile.

Company’s technology can be utilized in the following scenarios:

• Phenotype Based Drug Discovery – Identify the targets of bioactive molecule to allow ‘lead-optimization’

• Target Based Drug Discovery – Identify the off-targets of lead compounds from human cell models to assist in the ‘lead optimization’ and ‘candidate-selection’

• Drug Repositioning / Repurposing – Identify newer targets of existing drugs to provide a scientific and rational basis for repurposing